NCT06261918View on ClinicalTrials.gov

Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome

RecruitingOBSERVATIONAL

Enrollment

120

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

July 1, 2026

Conditions

Breast CancerMetabolic Syndrome

Interventions

PROCEDURE

Influence of metabolic syndrome on the achievement of pathological complete response

The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.

Trial Locations (1)

Unknown

RECRUITING

Fondazione Policlinico Universitario A. Gemelli - IRCCS, Roma

All Listed Sponsors

lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER